Search

Displaying results 341 - 350 of 4587 in total
  1. Drug

    Teplizumab

    go.drugbank.com/drugs/DB06606
    ApprovedInvestigational

    Teplizumab was designed as an Fc-non-binding antibody in order to reduce the incidence of CRS. … [A241490] Anti-CD3 therapy has traditionally been used to prevent graft-versus-host-disease in organ transplantation but more recently has been explored to prolong the onset of (T1D) in high-risk patients

  2. Drug

    Ethylhexyl methoxycrylene

    go.drugbank.com/drugs/DB11226
    Approved

    Ethylhexyl methoxycrylene is a photostabilizer that preserves the effectiveness of UV filters by interacting with both the singlet and triplet states [F104]. … It returns UV filters to their ground states without absorbing sunlight [F104].

  3. Drug

    Diamorphine

    go.drugbank.com/drugs/DB01452
    ApprovedIllicit

    As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom. … Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs.

  4. Drug

    Carbidopa

    go.drugbank.com/drugs/DB00190
    ApprovedInvestigational

    [L5110] On the other hand, the combination treatment of carbidopa/levodopa was originally developed by Watson Labs but the historical information by the FDA brings back to the approval of this combination … therapy developed by Mayne Pharma in 1992.

  5. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age. … [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.

  6. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    In order to improve drug delivery to the target organ, ranibizumab is available for intravitreal use. … [A246399] Ranibizumab was initially approved by the FDA in 2006 [A2301] and by the European Commission (EC) in 2007.[L41429] It is marketed under the brand names LUCENTIS and SUSVIMO.

  7. Drug

    Davamotecan pegadexamer

    go.drugbank.com/drugs/DB05899
    Investigational

    EP0057 is a conjugate of Insert's proprietary drug delivery molecule, Cyclosert, and the potent anti-cancer compound [camptothecin].

  8. Drug

    EGEN-001

    go.drugbank.com/drugs/DB05953
    Investigational

    EGEN-001 is a novel non-viral vector consisting of a plasmid DNA encoding the human gene for interleukin 12 (IL-12) and a biocompatible, biodegradable delivery polymer with potential antineoplastic activity

    Categories: Drug Delivery Systems
  9. Drug

    Bulevirtide

    go.drugbank.com/drugs/DB15248
    ApprovedInvestigational

    It was first approved for use in the EU on May 28, 2020; bulevirtide has been granted PRIME scheme eligibility and Orphan Drug Designation by the European Medicines Agency. … [A226305] Bulevirtide, also known as Hepcludex, is a first-in-class entry inhibitor for the treatment of chronic Hepatitis D infection developed by MYR Pharmaceuticals, now part of Gilead.

  10. Drug

    Tocofersolan

    go.drugbank.com/drugs/DB11635
    Approved

    In addition to the above, tocofersolan has been studied as a promising application as an absorption enhancer in drug delivery [MSDS]. … It was approved by the European Medicines Agency (EMA) in June 2009 under the market name Vedrop.